For patients with breast cancer, oral bisphosphonates may reduce risk for developing bone metastases
the ONA take:
According to a new study published in the Journal of the National Cancer Institute, researchers at the Research Institute of the McGill University Health Centre in Montreal, Quebec, Canada, oral bisphosphonates taken by postmenopausal women to treat osteoporosis may also slow skeletal metastases caused by breast cancer.
For the study, the researchers identified more than 21,000 women diagnosed with breast cancer. The researchers looked at the relationship between oral bisphosphonates, such as alendronate and risedronate, and the development of skeletal metastases after the patients were diagnosed with breast cancer. The patients were divided into two groups: those with early stage, localized cancer and those with locally advanced breast cancer.
The researchers found that women with early stage, localized breast cancer who had taken oral bisphosphonates before or after their cancer diagnosis had a decreased risk for developing bone metastases compared with women with locally advanced breast cancer.
Furthermore, women with locally advanced who received bisphosphonates after being diagnoses had a significantly decreased risk for developing bone metastases compared with those who did not take bisphosphonates. Women who took oral bisphosphonates for a longer period of time had a larger reduction of bone metastases.
Oral bisphosphonates for osteoporosis may also slow metastases from breast cancer.
Treatment approaches to reduce the risk of bone complications (metastasis) associated with breast cancer may be one step closer to becoming a reality. According to a study led by a team at the Research Institute of the McGill University Health Centre (RI-MUHC), findings show that medication used to treat bone deterioration in post-menopausal women may also slow skeletal metastasis caused from breast cancer.
This study, published in this month's issue of the Journal of the National Cancer Institute (JNCI), is among the first to link bisphosphonate (a common osteoporosis medication) use with improved survival in women with breast cancer. "Skeletal metastases develop in up to 70 percent of women who die from breast cancer," says study co-lead author, Dr. Richard Kremer, director of the Bone and Mineral Unit at the MUHC and a professor in the Faculty of Medicine at McGill University. "This causes considerable suffering and is life-threatening. Preventing this could translate into saving a significant number of lives."
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|